BioCryst wins US contract to continue Ebola drug development

March 31, 2015 12:33 PM

16 0

(Reuters) - BioCryst Pharmaceuticals Inc said it won a U.S. government contract to continue development of its potential treatment for Ebola and other viral diseases.

The 18-month contract includes a base value of $12.1 million to support manufacturing and up to $22.9 million in conditional funding.

Also read: CrowdStrike raises $200 million, continues to evaluate IPO: CEO

Read more

To category page